Fair Value Measurements And Financial Instruments (Tables)

12 Months Ended

Jan. 03, 2015

Fair Value Disclosures [Abstract]

Summary Of Financial Assets Measured At Fair Value On A Recurring Basis

A summary of assets and liabilities measured at fair value on a recurring basis as of January 3, 2015 and December 28, 2013 is as follows (in millions):

	Balance Sheet Classification	January 3, 2015		Quoted Prices In Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets
Money-market securities	Cash and cash equivalents	$	729	$	729	$	—	$	—
Available-for-sale securities	Other current assets	30		30		—		—
Trading securities	Other assets	301		301		—		—
Total assets		$	1,060	$	1,060	$	—	$	—
Liabilities
Contingent consideration	Other liabilities	$	50	$	—	$	—	$	50
Total liabilities		$	50	$	—	$	—	$	50

	Balance Sheet Classification	December 28, 2013		Quoted Prices In Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets
Money-market securities	Cash and cash equivalents	$	875	$	875	$	—	$	—
Available-for-sale securities	Other current assets	35		35		—		—
Trading securities	Other assets	279		279		—		—
Total assets		$	1,189	$	1,189	$	—	$	—
Liabilities
Contingent consideration	Other liabilities	$	195	$	—	$	—	$	195
Total liabilities		$	195	$	—	$	—	$	195

Fair Value Inputs, Liabilities, Quantitative Information [Table Text Block]

The recurring Level 3 fair value measurements of the Company's contingent consideration liability include the following significant unobservable inputs (in millions):

Contingent Consideration Liability	Fair Value as of January 3, 2015		Valuation Technique	Unobservable Inputs
Nanostim regulatory-based milestone	$	50	Probability Weighted Discounted Cash Flow	Discount Rate		5.00%
				Probability of Payment		95%
				Projected Years of Three Annual Payments	2016, 2017, 2018
Total contingent consideration liability	$	50

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

Additionally, the following table provides a reconciliation of the beginning and ending balances of the Company's contingent consideration liabilities associated with its Endosense acquisition subsequent to the August 19, 2013 acquisition date and its Nanostim acquisition subsequent to the October 11, 2013 acquisition date, as of January 3, 2015 (in millions):

	Endosense			Nanostim			Total
Balance as of December 29, 2012	$	—		$	—		$	—
Purchase price contingent consideration	132			56			188
Change in fair value of contingent consideration	1			—			1
Foreign currency translation	6			—			6
Balance as of December 28, 2013	139			56			195
Change in fair value of contingent consideration	28			(6		)	22
Payment of contingent consideration	(155		)	—			(155		)
Foreign currency translation	(12		)	—			(12		)
Balance as of January 3, 2015	$	—		$	50		$	50